Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 132 of 151

  1. Tridecanoic Acid

    Ultragenyx UK Limited

    Rett Syndrome

    phase 2 small molecule active

    1 trial

  2. Trientine

    United Therapeutics Europe Ltd

    Hypertrophic Cardiomyopathy

    phase 2 small molecule completed

    1 trial

  3. Triheptanoin

    Ultragenyx UK Limited

    Glycogen Storage Disease Type V

    phase 2 small molecule completed

    1 trial

  4. Triheptanoin

    Ultragenyx UK Limited

    Glucose Transporter Type 1 Deficiency Syndrome

    phase 2 small molecule active

    1 trial

  5. Triheptanoin

    Ultragenyx UK Limited

    Adult Polyglucosan Body Disease

    phase 2 small molecule completed

    1 trial

  6. Triheptanoin

    Ultragenyx UK Limited

    Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)

    phase 2 small molecule completed

    1 trial

  7. Triheptanoin

    Ultragenyx UK Limited

    Medium-chain Acyl-CoA Dehydrogenase Deficiency

    phase 2 small molecule active

    2 trials

  8. Triheptanoin

    Ultragenyx UK Limited

    ALS

    phase 2 small molecule completed

    1 trial

  9. Triheptanoin

    Ultragenyx UK Limited

    Tarui Disease

    phase 2 small molecule completed

    1 trial

  10. Triheptanoin oil

    Ultragenyx UK Limited

    Huntington Disease

    phase 2 small molecule completed

    1 trial

  11. Trilaciclib

    The First People's Hospital of Lianyungang

    Advanced Squamous Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Trilaciclib

    The First People's Hospital of Lianyungang

    Osteosarcoma

    phase 2 small molecule active

    1 trial

  13. Trilaciclib and Sacituzumab Tirumotecan

    The First People's Hospital of Lianyungang

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  14. Trimeton / soluzione iniettabile for Primary Membranous Nephropathy

    Istituto Gentili S.r.l.

    Primary Membranous Nephropathy

    phase 2 small molecule active

    1 trial

  15. Trivalent influenza vaccine (TIVc)

    Seqirus (Australia) Pty Ltd

    Influenza

    phase 2 mab completed

    1 trial

  16. Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  17. Tumor infiltrating lymphocytes (TIL) LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  18. Tunlametinib+PD-1 mAb

    BEONE MEDICINES AUS PTY LTD

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  19. Tuspetinib

    Aptose Biosciences

    Leukemia, Myeloid, Acute

    phase 2 small molecule active

    1 trial

  20. TwHF

    Beijing 302 Hospital

    Human Immunodeficiency Virus

    phase 2 small molecule active

    1 trial

  21. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  22. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  23. Tyrosine

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine-Related Disorders

    phase 2 other completed

    1 trial

  24. U1111-1305-0044

    The George Institute

    Early triple-negative breast cancer (TNBC)

    phase 2 other active

    1 trial

  25. UB-221

    United Therapeutics Europe Ltd

    Chronic Spontaneous Urticaria

    phase 2 mab active

    1 trial

  26. UB-311

    United Therapeutics Europe Ltd

    Alzheimer's Disease

    phase 2 mab terminated

    3 trials

  27. UB-421

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV-1-infection

    phase 2 mab active

    1 trial

  28. UB-421(25 mg/kg) Q2W

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV-1-infection

    phase 2 mab active

    1 trial

  29. UB-421(25 mg/kg) Q2W

    United Therapeutics Europe Ltd

    HIV-1 Infection

    phase 2 mab completed

    1 trial

  30. UB-612

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 mab completed

    4 trials

  31. UB-621

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Recurrent Genital Herpes

    phase 2 mab active

    1 trial

  32. UB-621

    United Therapeutics Europe Ltd

    Genital Herpes

    phase 2 mab active

    1 trial

  33. UBT251

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule active

    1 trial

  34. UBT251

    United Therapeutics Europe Ltd

    Metabolic Dysfunction-associated Steatohepatitis (MASH)

    phase 2 small molecule active

    1 trial

  35. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule completed

    1 trial

  36. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule completed

    1 trial

  37. UC-0107/1810

    Ningbo Cancer Hospital

    BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)

    phase 2 small molecule active

    1 trial

  38. UC-0110/1608

    Ningbo Cancer Hospital

    RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method

    phase 2 small molecule active

    1 trial

  39. UC-0110/1719

    Ningbo Cancer Hospital

    Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy

    phase 2 small molecule active

    1 trial

  40. UC-0140/1711_UCBG3

    Ningbo Cancer Hospital

    Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.

    phase 2 small molecule active

    1 trial

  41. UC-0140/1812

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  42. UC-0150/1704

    Ningbo Cancer Hospital

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  43. UC-BCG-2011

    Ningbo Cancer Hospital

    HER2+ metastatic breast cancer with isolated brain progression

    phase 2 small molecule active

    1 trial

  44. UC-BCG-2103

    Ningbo Cancer Hospital

    Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse

    phase 2 small molecule active

    1 trial

  45. UC-BCG-2211, CAPPA

    Ningbo Cancer Hospital

    Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.

    phase 2 small molecule active

    1 trial

  46. UC-BCG-2213

    The George Institute

    Triple negative breast cancer

    phase 2 small molecule active

    1 trial

  47. UC-BCG-2312

    Ningbo Cancer Hospital

    Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy

    phase 2 small molecule active

    1 trial

  48. UC-BCG-2513

    Ningbo Cancer Hospital

    Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.